Random Transgenic

TNF-α Random Transgenic Mouse Model

C57BL/6NTac Background

  • Model #
  • Genotype
  • Nomenclature
  • 1006-F
    B6.Cg(SJL)-Tg(TNF) N21+?
  • 1006-M
    B6.Cg(SJL)-Tg(TNF) N21+?
  • 1006-F
    B6.Cg(SJL)-Tg(TNF) N21+?
  • 1006-M
    B6.Cg(SJL)-Tg(TNF) N21+?
  • Express the human tumor necrosis factor α (TNF-α) transgene, a cytokine implicated in the pathogenesis of human rheumatoid arthritis
  • Exhibits severe chronic arthritis of the forepaws and hind paws, as shown by gross observation and histological analysis by approximately 20 weeks of age
  • A useful model for studying inflammatory arthritis which does not require experimental manipulation

Genetic Background:

C57BL/6 Background


The TNF-α mouse was developed by Xenogen Biosciences, now Taconic. The model was created by microinjecting the human TNF-α gene. Taconic received stock in April 1996 at the second backcross from the C57BL/6 x SJL founder line. The mice were maintained by backcrossing hemizygous TNF-α mice to C57BL/6NTac inbred mice.





Initial Publication:

Hayward MD, Jones BK, Saparov A, Hain HS, Trillat A-C, Bunzel MM, Corona A, Li-Wang B, Strenkowski B, Giordano C, Shen H, Arcamone E, Weidlick J, Vilensky M, Tugusheva M, Felkner RH, Campbell W, Rao Y, Grass DS, Buiakova O. (2007) An extensive phenotypic characterization of the hTNFα transgenic mice. BMC Physiology, 7:13.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:

  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred except to obtain embryos or fetuses required for research purposes
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.

Phenotypic Disease Observations:

Onset of Arthritis-Clinical Signs in Hindlimbs
TNF-α Transgenic Mice and non-transgenic age-matched controls comparing signs of disease progression.

5 weeks: normal appearance; no detectable symptoms
TNF-α at 5 weeks

9 weeks: mild disease; minor loss of flexibility in digits; minimal joint swelling and distortion
TNF-α at 9 weeks

14 weeks: moderate disease; moderate distortion and twisting of hindpaw and moderate swelling of joints
TNF-α at 14 weeks

20 weeks: severe disease; distortion and swelling of joints
TNF-α at 20 weeks